Results for the Fourth Quarter and Preliminary Results for 2022

Posted on by Medistim ASA

Another record quarter ending at MNOK 141.8 in sales (MNOK 112.7). Full-year revenue at MNOK 491.9 (MNOK 427.3) is also a new record, up 15.1 %

All major geographical regions drive sales growth. Currency-neutral sales increased by 21.6 % for the quarter and 11.9 % for the year. Currency-neutral sales of own products increase 24.6 % for the quarter and 14.0 % for the year. The Vascular business segment grows 8.8 % for the quarter and 27.3 % for the year. The Imaging products grow 33.5 % for the quarter and 44.0 % for the year. Operating profit (EBIT) for the quarter ended at MNOK 36.5 (MNOK 19.5), with an EBIT margin of 25.7 % (17.3 %). For the year, EBIT ended at MNOK 141.3 (MNOK 116.3), with an EBIT margin of 28.7 % (27.6 %). The board suggests a dividend of NOK 4.5 (NOK 3.75) per share to the General Meeting, a total dividend payout of MNOK 82.1

Download the full presentation and report and watch the video recording from the webinar below.

Q4 2022 Presentation
Q4 2022 Financial Report